Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI109404

Effect of Intermittent Endogenous Hyperglucagonemia on Glucose Homeostasis in Normal and Diabetic Man

Robert Rizza, Carlos Verdonk, John Miles, F. John Service, and John Gerich

Diabetes and Metabolism Research Laboratory, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Medicine, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Physiology, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Find articles by Rizza, R. in: PubMed | Google Scholar

Diabetes and Metabolism Research Laboratory, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Medicine, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Physiology, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Find articles by Verdonk, C. in: PubMed | Google Scholar

Diabetes and Metabolism Research Laboratory, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Medicine, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Physiology, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Find articles by Miles, J. in: PubMed | Google Scholar

Diabetes and Metabolism Research Laboratory, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Medicine, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Physiology, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Find articles by Service, F. in: PubMed | Google Scholar

Diabetes and Metabolism Research Laboratory, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Medicine, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Endocrine Research Unit, Department of Physiology, Mayo Clinic and Medical School, Rochester, Minnesota 55901

Find articles by Gerich, J. in: PubMed | Google Scholar

Published June 1, 1979 - More info

Published in Volume 63, Issue 6 on June 1, 1979
J Clin Invest. 1979;63(6):1119–1123. https://doi.org/10.1172/JCI109404.
© 1979 The American Society for Clinical Investigation
Published June 1, 1979 - Version history
View PDF
Abstract

Infusion of glucagon causes only a transient increase in glucose production in normal and diabetic man. To assess the effect of intermittent endogenous hyperglucagonemia that might more closely reflect physiologic conditions, arginine (10 g over 30 min) was infused four times to 8 normal subjects and 13 insulin-dependent diabetic subjects (4 of whom were infused concomitantly with somatostatin to examine effects of arginine during prevention of hyperglucagonemia). Each arginine infusion was separated by 60 min. Diabetic subjects were infused throughout the experiments with insulin at rates (0.07-0.48 mU/kg per min) that had normalized base-line plasma glucose and rates of glucose appearance (Ra) and disappearance (Rd). Basal plasma glucagon and arginine-induced hyperglucagonemia were similar in both groups; basal serum insulin in the diabetics (16±1 μU/ml, P < 0.05) exceeded those of the normal subjects (10±1 μU/ml, P < 0.05) but did not increase with arginine. Serum insulin in normal subjects increased 15-20 μU/ml with each arginine infusion. In both groups each arginine infusion increased plasma glucose and Ra. Increments of Ra in the diabetics exceeded those of normal subjects, (P < 0.02); Rd was similar in both groups. In normal subjects, plasma glucose returned to basal levels after each arginine infusion, whereas in the diabetics hyperglycemia persisted reaching 151±15 mg/dl after the last arginine infusion. When glucagon responses were prevented by somatostatin, arginine infusions did not alter plasma glucose or Ra.

Conclusions: Infusion of arginine acutely increases plasma glucose and glucose production in man solely by stimulating glucagon secretion; physiologic increments in plasma glucagon (100-150 pg/ml) can result in sustained hyperglycemia when pancreatic beta cell function is limited.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1119
page 1119
icon of scanned page 1120
page 1120
icon of scanned page 1121
page 1121
icon of scanned page 1122
page 1122
icon of scanned page 1123
page 1123
Version history
  • Version 1 (June 1, 1979): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts